# Estimated glucose disposal rate and non-HDL-c/HDL-c ratio with the progression of carotid atherosclerosis: a long-term cohort study

**Authors:** Bingqing Han, Jing Ma, Shanshan Liu, Chao Fu, Hao Zhang, Yi Luo, Fei Wang, Qiang Zeng

PMC · DOI: 10.3389/fmed.2025.1627246 · Frontiers in Medicine · 2025-07-17

## TL;DR

This study shows that combining measures of glucose disposal and cholesterol ratios improves prediction of carotid atherosclerosis progression.

## Contribution

The study demonstrates that combining eGDR and NHHR improves CAS progression prediction beyond traditional models.

## Key findings

- A non-linear relationship exists between eGDR and CAS progression.
- Higher NHHR is linearly associated with increased CAS progression risk.
- Combining eGDR and NHHR significantly improves CAS progression prediction.

## Abstract

Both the estimated glucose disposal rate (eGDR) and the non-HDL-c/HDL-c ratio (NHHR) are associated with cardiovascular disease risk and prognosis. It is unclear whether assessing eGDR and NHHR together improves CAS progression prediction.

This large cross-sectional and longitudinal cohort study included 7,360 adults who underwent multiple health check-ups at the Chinese PLA General Hospital from October 2009 to December 2023. The relationships of the eGDR and NHHR with CAS progression were determined through multivariable Cox regression analysis and restricted cubic splines (RCS).

During a median follow-up period of 30 months, we included 7,360 participants. The restricted cubic spline curve of the correlation between the eGDR and CAS progression was non-linear. There was a positive linear relationship between the NHHR and CAS progression. When the eGDR was <8.71 (median level) mg/kg/min and the NHHR was >2.89, the risk of CAS progression significantly increased. Subgroup analysis revealed that age significantly altered the correlation. The incorporation of the eGDR and NHHR into the basic model significantly enhanced the usefulness of the model for predicting CAS progression. Furthermore, mediation analysis revealed that the NHHR significantly mediated the impact of the eGDR on CAS progression.

This study revealed that a lower eGDR and higher NHHR are associated with an increased risk of CAS progression. The combined assessment of the eGDR and NHHR can enhance the identification of high-risk populations, which is useful for the implementation of active preventive measures.

## Linked entities

- **Diseases:** cardiovascular disease (MONDO:0004995)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, BCAR1 (BCAR1 scaffold protein, Cas family member) [NCBI Gene 9564] {aka CAS, CAS1, CASS1, CRKAS, P130Cas}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, LPL (lipoprotein lipase) [NCBI Gene 4023] {aka HDLCQ11, LIPD}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}
- **Diseases:** obesity (MESH:D009765), CAD (MESH:D003324), myocardial infarction (MESH:D009203), prediabetes (MESH:D011236), eGDR (MESH:D018149), reduction of muscle mass (MESH:C536030), death (MESH:D003643), NHHR (MESH:D052456), Cardiovascular disease (MESH:D002318), Carotid atherosclerosis (MESH:D002340), HTN (MESH:D006973), dyslipidemia (MESH:D050171), type 1 diabetes (MESH:D003922), hyperglycemia (MESH:D006943), IR (MESH:D007333), stroke (MESH:D020521), diabetes (MESH:D003920), abnormal lipid metabolism (MESH:D052439), CF (MESH:D003550), atherosclerotic plaques (MESH:D058226), ASCVD (MESH:D050197), metabolic syndrome (MESH:D024821), hyperinsulinemic (MESH:D044903), coronary heart disease (MESH:D003327), acute diseases (MESH:D000208), type 1 or type 2 diabetes (MESH:D003924), Sarcopenia (MESH:D055948), deficiency of nitric oxide (MESH:D028361), Abnormal glucose metabolism (MESH:D044882), metabolic disorders (MESH:D008659), malignancy (MESH:D009369), Carotid plaques (MESH:D016893), inflammation (MESH:D007249)
- **Chemicals:** alcohol (MESH:D000438), uric acid (MESH:D014527), lipid (MESH:D008055), TG (MESH:D014280), prostacyclin (MESH:D011464), cholesterol (MESH:D002784), glucose (MESH:D005947), creatinine (MESH:D003404), FBG (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12310652/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12310652/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12310652/full.md

---
Source: https://tomesphere.com/paper/PMC12310652